JEIL PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17,160 KRW | +1.00% |
|
-3.54% | +0.35% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 532,316 | 914,865 | 494,458 | 306,002 | 249,173 |
| Enterprise Value (EV) 1 | 551,220 | 957,581 | 514,255 | 328,763 | 284,686 |
| P/E ratio | -51.9 x | 132 x | -39.6 x | -23.4 x | 49.8 x |
| Yield | - | 0.11% | 0.19% | 0.24% | 0.29% |
| Capitalization / Revenue | 0.79 x | 1.32 x | 0.71 x | 0.42 x | 0.34 x |
| EV / Revenue | 0.82 x | 1.39 x | 0.73 x | 0.46 x | 0.39 x |
| EV / EBITDA | 76.5 x | 44.7 x | -412 x | -73.9 x | 15.3 x |
| EV / FCF | - | -44,196,701 x | 25,408,000 x | 81,138,905 x | 98,807,106 x |
| FCF Yield | - | -0% | 0% | 0% | 0% |
| Price to Book | 3.13 x | 5.3 x | 2.93 x | 1.94 x | 1.57 x |
| Nbr of stocks (in thousands) | 14,705 | 14,614 | 14,607 | 14,572 | 14,572 |
| Reference price 2 | 36,200 | 62,600 | 33,850 | 21,000 | 17,100 |
| Announcement Date | 3/15/21 | 3/15/21 | 3/15/22 | 3/16/23 | 3/12/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | 671,407 | 691,325 | 700,693 | 722,230 | 726,394 |
| EBITDA 1 | 7,202 | 21,420 | -1,247 | -4,446 | 18,655 |
| EBIT 1 | -544.9 | 12,427 | -10,380 | -13,332 | 8,888 |
| Operating Margin | -0.08% | 1.8% | -1.48% | -1.85% | 1.22% |
| Earnings before Tax (EBT) 1 | -554.1 | 12,552 | -13,834 | -13,247 | 1,916 |
| Net income 1 | -10,239 | 6,916 | -12,473 | -13,091 | 5,005 |
| Net margin | -1.53% | 1% | -1.78% | -1.81% | 0.69% |
| EPS 2 | -698.0 | 473.0 | -853.8 | -898.2 | 343.5 |
| Free Cash Flow | - | -21,666 | 20,240 | 4,052 | 2,881 |
| FCF margin | - | -3.13% | 2.89% | 0.56% | 0.4% |
| FCF Conversion (EBITDA) | - | - | - | - | 15.44% |
| FCF Conversion (Net income) | - | - | - | - | 57.57% |
| Dividend per Share | - | 70.00 | 65.00 | 50.00 | 50.00 |
| Announcement Date | 3/15/21 | 3/15/21 | 3/15/22 | 3/16/23 | 3/12/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | 18,904 | 42,716 | 19,797 | 22,761 | 35,513 |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.625 x | 1.994 x | -15.87 x | -5.119 x | 1.904 x |
| Free Cash Flow | - | -21,666 | 20,240 | 4,052 | 2,881 |
| ROE (net income / shareholders' equity) | - | 4.08% | -8.82% | -9.06% | 3.11% |
| ROA (Net income/ Total Assets) | - | 1.92% | -1.55% | -1.89% | 1.18% |
| Assets 1 | - | 360,684 | 803,846 | 693,925 | 425,357 |
| Book Value Per Share 2 | 11,554 | 11,800 | 11,534 | 10,837 | 10,882 |
| Cash Flow per Share 2 | 925.0 | 267.0 | 1,780 | 2,158 | 2,264 |
| Capex 1 | 1,086 | 2,410 | 5,344 | 11,085 | 6,097 |
| Capex / Sales | 0.16% | 0.35% | 0.76% | 1.53% | 0.84% |
| Announcement Date | 3/15/21 | 3/15/21 | 3/15/22 | 3/16/23 | 3/12/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +0.35% | 185M | |
| +21.98% | 43.92B | |
| +24.56% | 23.09B | |
| +19.07% | 15.35B | |
| +14.03% | 13.61B | |
| +46.40% | 12.02B | |
| -10.14% | 7B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.07% | 5.6B |
- Stock Market
- Equities
- A271980 Stock
- Financials Jeil Pharmaceutical Co.,Ltd